The Effects of Staggered Dosing on Interactions Between Paired Combinations of Nelfinavir, Ritonavir, and Saquinavir
NCT ID: NCT00000898
Last Updated: 2021-10-29
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
18 participants
INTERVENTIONAL
2000-05-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
TREATMENT
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Ritonavir
Nelfinavir mesylate
Saquinavir
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Absence of HIV-1 infection as documented by any licensed ELISA test kit within 14 days prior to study entry.
Exclusion Criteria
Patients with the following symptoms and conditions are excluded:
* Any medical condition that, in the opinion of the investigator, would interfere with the patient's ability to participate in this protocol.
Patients with the following prior conditions and symptoms are excluded:
* History of chronic illness such as hypertension, coronary artery disease, arthritis, diabetes, or any chronic gastrointestinal conditions that might interfere with drug absorption.
18 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Blaschke T
Role: STUDY_CHAIR
Flexner C
Role: STUDY_CHAIR
Sheiner L
Role: STUDY_CHAIR
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
San Francisco Gen Hosp
San Francisco, California, United States
Univ of California/ San Francisco / Dept of Medicine
San Francisco, California, United States
Stanford Univ Med Ctr
Stanford, California, United States
Johns Hopkins Hosp
Baltimore, Maryland, United States
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Washington CB, Flexner C, Sheiner LB, Rosenkranz SL, Segal Y, Aberg JA, Blaschke TF; AIDS Clinical Trials Group Protocol (ACTG 378) Study Team. Effect of simultaneous versus staggered dosing on pharmacokinetic interactions of protease inhibitors. Clin Pharmacol Ther. 2003 May;73(5):406-16. doi: 10.1016/s0009-9236(03)00006-7.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
11339
Identifier Type: REGISTRY
Identifier Source: secondary_id
ACTG 378
Identifier Type: -
Identifier Source: org_study_id